


SELIC Q2/2023 OPPORTUNITY DAY

Sep 29th 2023



COMPANY OVERVIEW

COMPANY STRUCTURE



GOVERNANCE & SUSTAINABILITY DEVELOPMENT



ผลการประเมิน CGR CHECKLIST ปี 2565 โครงการสำรวจการกำกับดูแลกิจการบริษัทจดทะเบียนไทย Corporate Governance Report of Thai Listed Companies ได้ 94 คะแนน ระดับดีเลิศ (Excellent)



โครงการประเมินคุณภาพการจัดประชุมสามัญผู้ถือหุ้นประจำปี 2566 ได้คะแนน AGM CHECKLIST 95 เต็ม 100 คะแนน



้เกียรติบัตรโครงการแนวร่วมปฏิบัติของภาคเอกชนไทยในการต่อต้านการทูจริต Certificate of Membership Thailand's Private Sector Collective Action Coalition Against Corruption (CAC)

โครงการแนวร่วมปฏิบัติของภาคเอกชนไทยในการต่อต้านการทูจริต







ได้รับการคัดเลือกเข้าสู่รายชื่อหุ้นยั่งยืน หรือ Thailand Sustainability Investment Ü 2565 ตลาดหลักทรัพย์แห่งประเทศไทย





รางวัลเกียรติยศแห่งความสำเร็จ SET Awards 2022: Commended Sustainability Awards ตลาดหลักทรัพย์แห่งประเทศไทย







รางวัล CAC Change Agent Award 2022 แนวร่วมต่อต้านคอร์รัปชั่นของภาคเอกชนไทย (Thai Private Sector Collective Action Against Corruption - CAC)

โครงการรางวัลองค์กรต้นแบบความยั่งยืนตลาดทุนไทย ด้านสนับสนุนคนพิการ รางวัลดีเด่น สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาด หลักทรัพย์

BUSINESS OVERVIEW

ADHESIVE BUSINESS

SELF-ADHESIVE LABEL BUSINESS

CONSUMER
HEALTHCARE
BUSINESS

Innovation นวัตกรรม

ผลักดันกระบวนการคิดแบบ innovative thinking และส่งเสริม เพื่อให้เป็นองค์กรนวัตกรรม Heart of Customer อยู่ในหัวใจของลูกค้า

การบริการและแนวทางในการบริหาร ความสัมพันธ์กับลูกค้าใช้หลักการ customer centric เพื่อตอบโจทย์ทางธุรกิจของลูกค้า

OUR ADHESIVE TECHNOLOGIES AND PRODUCTS

Solvent Based

เป็นกาวที่อยู่ในสถานะ ของเหลว ใช้ตั้วทำละลาย ประเภท Solvent ในกลุ่ม ของน้ำมัน หรือทินเนอร์ เป็นตัวทำละลาย

Water Based

เป็นผลิตภัณฑ์กาว สังเคราะห์และใช้น้ำเป็นตัว ละลาย ทำให้กาวมีสภาพ เป็นของเหลว ใช้งานง่าย

Hotmelt

มีคุณลักษณะเป็นของแข็ง ใช้งาน ผ่านความร้อนเพื่อให้กาวละลาย กลายเป็นของเหลวเมื่อเนื้อกาวเย็น ลง จะยึดติดวัสดุ 2 ชิ้นเข้าด้วยกัน

Hotmelt PUR

เป็นกาวในกลุ่ม hot melt แต่ ต่างกันที่คุณสมบัติคงทน โดยเมื่อ เกิดการยึดติดแล้วจะไม่แปลงสภาพ เหมาะกับงานที่ต้องการความ ทนทาน



















END MARKET SECTORS



Food & beverage
Footwear
Consumer products
Printing
Furniture
Construction
Automotive
Etc.

WHAT IS SELF ADHESIVE LABEL?

The component



Facestock สำหรับใช้พิมพ์ กาวทำหน้าที่ติด facestock กับผลิตภัณฑ์ หรือสิ่งของ

ม้วนใหญ่ Master roll



กระดาษเคลือบด้วยซิลิโคน

ม้วนสำเร็จรูป



แผ่นสำเร็จรูป

END MARKETS OF LABEL STOCK BUSINESS



Food & Beverage



Product ID



Advertising & Retail



Consumer Products



Logistics and Transportation



Industrial



CONSUMER HEALTHCARE RANGE OF PRODUCTS

Brand

Namman Muay/ Muay

Neoplast

Neobun/ Mentopas

Neotape

Product

Liniment



Bandage



Analgesic



Neobun



Tape





Product Category

Cream



Spray




Fever Cooling Roots Patch

Alcohol Pad




10

TARGET CUSTOMER















FINANCIAL PERFORMANCE


REVENUE


Q2/23 revenue recorded at 456.2 million with 0.3% growth compared to previous quarter and 16.8% growth compared to the same period of previous year. Revenue recognition of the consumer healthcare segment was significantly growing due to increasing of the production capacity and distributing more variety of products into the market.




RELATED ECONOMY KEY INDICATORS









Q2/23 overall Thailand GDP increased by 1.8% (YoY) mainly from service sector while continuously decreased in industrial sector


Indicators that related to Selic's sales such as MPI, manufacturing GDP, and export of goods GDP did show continuously negative sign when compare as YoY and no significant movement in the past few quarters


Source: "Gross Domestic Product: Q2/2023 Report" Office of the National Economic and Social Development Council

SALES BY SEGMENT and MARKET DESTINATION

Sales recorded at 455.7 million with 0.9% growth compared to previous quarter and 16.9% growth compared to the same period of previous year where the growth was mainly from consumer healthcare segment while sales of adhesive and self-adhesive label segment decreased mainly from export market.

A significant growth in domestic sales as consolidation of consumer healthcare segment which mainly sales in domestic market while export sales of adhesive and self-adhesive dropped.






COST OF SALES AND GROSS PROFIT

Q2/23 gross profit amount recorded at 124.0 million increased 21.0% and 43.1% compared to previous quarter and the same period of previous year respectively. Increasing sales and high gross profit margin of consumer healthcare segment did drive good result of overall gross profit amount and margin. Even oil price slightly dropped in Q2/2023 but with high price competition in oversea market together with raw material stock time lag then gross profit margin of adhesive and self-adhesive label have not increased yet.

Crude Oil WTI (USD/Bbl) 90.154 +0.501 (+0.56%) Q1/23 Q2/23 Q2/23 85 80 75 70







SG&A

Q2/23 SG&A increased by 2.6 million (+3.2% QoQ) and 16.1 million (+23.6% YoY) with 18.5% SG&A to revenue ratio


- Admin expense increased by 1.3 million (+2.4% QoQ) and 9.0 million (+19.2% YoY)
- selling expense increased 1.3 million (+4.7% QoQ) and 7.1 million (+33.4% YoY)






PROFITABILITY

- EBITDA was 57.5 million with EBITDA ratio at 12.6%
- Net profit was 21.7 million with net profit ratio at 4.7%







SEGMENT PERFORMANCE

REVENUE & SALES

Q2/23 sales recorded at 133.8 million declined -16.2% from previous quarter and -23.2% from the same period of previous year


Domestic sales declined -17.5% QoQ and -13.6% YoY. Export sales declined -14.6% QoQ and -33.7% YoY

Unit: Million Baht 175.6 159.8 133.8 ▼ -16.2% QoQ ▼ -23.2% YoY Q2/22 Q1/23 Q2/23

By market destination



By product technology



FINANCIAL RESULTS

- Gross Profit decreased 6.7 million or -17.5% from previous quarter with gross profit margin at 23.6%
- SGA decreased 4.0 million or -13.5% from previous quarter with SGA ratio at 19.0%


19.0%

- EBITDA decreased 2.6 million or -18.3% from previous quarter with EBITDA ratio at 8.6%
- Net Profit decreased 2.0 million or -32.9% from previous quarter with net profit ratio at 3.1%

SG&A

18.4%


19.0%







EBITDA




^{*}exclusive of inter company dividend

REVENUE & SALES

Q2/23 sales recorded at 195.2 million declined -13.4% QoQ and -7.3% YoY.

Domestic sales declined -11.3% QoQ but increased +4.0% YoY.


Export sales declined at -17.6% QoQ and -24.9% YoY




By market destination



By product technology






REVENUE & SALES


Q2/23 sales recorded at 124.9 million increased 87.9% QoQ and 168.7% YoY mainly from increasing of production capacity and distributing more variety products of DVK Healthcare Co., Ltd.

Most product category did well for both QoQ and YoY



^{*} Figure before Devakam invests into DVK healthcare

By market destination



By product technology






LEVERAGE RATIO

PMCL acquisition		Devakam acquisition				
2019	2020	2021	2022	02		

Ratio	2018	2019	2020	2021	2022	Q2/2023
Total Debt (MB)	195	1,161	1,097	1,089	1,547	1,613
Total Equity (MB)	349	432	522	668	1,235	1,255
Interest-bearing Debt (MB)	69	681	592	507	886	863
D/E (x)	0.56	2.68	2.10	1.63	1.25	1.28
D/E (x) interest bearing debt	0.20	1.57	1.13	0.76	0.72	Ø.69





Q & A





This Presentation is not intended to provide the basis for any investment decision, nor to substitute your own analysis and investigation, and should not be considered as a recommendation to any recipient of this Presentation. Some statements made in this presentation are forward-looking statements, which are subject to various risks and uncertainties. These include statements with respect to the Company's corporate plans, strategies and beliefs and other statement that are not historical facts. These statement can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue", "plan" or other similar words.

The statements are based on the assumptions and beliefs of the Company's management in light of the information currently available to the Company. These assumptions involve risks and uncertainties which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Nothing in this Presentation is, or should be, relied on as promise or representation of the Company as to the future.



270 Liabklongphasicharoenfangtai, Nongkhaem, Bangkok 10160



02 8073347



investorrelation@seliccorp.com